Metis Global Partners LLC Has $1.32 Million Stock Position in STERIS plc (NYSE:STE)

Metis Global Partners LLC increased its holdings in shares of STERIS plc (NYSE:STE) by 1.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 5,450 shares of the medical equipment provider’s stock after purchasing an additional 84 shares during the period. Metis Global Partners LLC’s holdings in STERIS were worth $1,322,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Ashton Thomas Securities LLC bought a new position in shares of STERIS in the third quarter worth about $25,000. Central Pacific Bank Trust Division bought a new position in STERIS in the 3rd quarter valued at approximately $28,000. Quent Capital LLC boosted its position in STERIS by 112.7% in the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 71 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of STERIS during the first quarter worth $36,000. Finally, Versant Capital Management Inc increased its holdings in shares of STERIS by 2,262.5% during the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 181 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

Shares of STE stock opened at $220.12 on Friday. The stock has a market capitalization of $21.73 billion, a PE ratio of 50.26 and a beta of 0.85. The business’s 50 day simple moving average is $230.37 and its 200 day simple moving average is $228.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. STERIS plc has a one year low of $195.47 and a one year high of $248.24.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.02. The company had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.03 earnings per share. As a group, research analysts forecast that STERIS plc will post 9.15 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s dividend payout ratio is 52.05%.

Wall Street Analyst Weigh In

STE has been the topic of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. KeyCorp boosted their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and raised their price target for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

Insider Activity at STERIS

In other news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. The trade was a 35.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.14% of the stock is owned by corporate insiders.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.